Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Shares Outstanding (Diluted Average) (2016 - 2025)

Protalix BioTherapeutics has reported Shares Outstanding (Diluted Average) over the past 12 years, most recently at $76.6 million for Q1 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $76.6 million for Q1 2025, up 4.9% from a year ago — trailing twelve months through Mar 2025 was $76.6 million (up 4.9% YoY), and the annual figure for FY2022 was $48.5 million, up 9.81%.
  • Shares Outstanding (Diluted Average) for Q1 2025 was $76.6 million at Protalix BioTherapeutics, up from $73.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for PLX hit a ceiling of $78.9 million in Q2 2023 and a floor of $39.9 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $48.5 million (2022), compared with a mean of $55.6 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 69.34% in 2023 and later fell 7.25% in 2024.
  • Protalix BioTherapeutics' Shares Outstanding (Diluted Average) stood at $44.1 million in 2021, then increased by 9.81% to $48.5 million in 2022, then skyrocketed by 62.77% to $78.9 million in 2023, then fell by 7.25% to $73.2 million in 2024, then increased by 4.7% to $76.6 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $76.6 million (Q1 2025), $73.2 million (Q2 2024), and $73.0 million (Q1 2024) per Business Quant data.